<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01652820</url>
  </required_header>
  <id_info>
    <org_study_id>GECP 00-08 / TAX.ES1.209</org_study_id>
    <nct_id>NCT01652820</nct_id>
  </id_info>
  <brief_title>Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer</brief_title>
  <acronym>GECP0008</acronym>
  <official_title>Randomized Phase II Trial Using Concomitant Chemoradiation Plus Induction or Consolidation Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Lung Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Lung Cancer Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized study in 2 arms, without any masking in patients with non small cell lung cancer,
      histologically or cytologically confirmed, not liable to surgery, stage IIIB or IIIA,
      according to the TNM classification of the American Joint Committee for cancer. In one arm
      will be administered concomitant radiotherapy and carboplatin-docetaxel-gemcitabine followed
      by docetaxel and, in the other arm will be administered docetaxel-gemcitabine followed by
      concurrent radiotherapy with carboplatin-docetaxel
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local control rate at 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Non Small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel +Carboplatin +concomitant chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 20 mg/m2/weekly plus carboplatin AUC 2/weekly (first, docetaxel will be administered and after that, carboplatin will be administered) and concomitant chemoradiation (total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C) Docetax+ gemcit +concom. docetax + carbopl. + RDT concom</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 40 mg/ m2 days 1, 8, 21 y 28 plus gemcitabine 1200 mg/ m2 days 1, 8, 21 y 28 followed by concomitant treatment Docetaxel 20 mg/m2/week plus carboplatin AUC 2/weekly and concomitant chemoradiation total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day</intervention_name>
    <arm_group_label>Docetaxel +Carboplatin +concomitant chemoradiation</arm_group_label>
    <arm_group_label>C) Docetax+ gemcit +concom. docetax + carbopl. + RDT concom</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel 40mg&lt;7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d</intervention_name>
    <arm_group_label>Docetaxel +Carboplatin +concomitant chemoradiation</arm_group_label>
    <arm_group_label>C) Docetax+ gemcit +concom. docetax + carbopl. + RDT concom</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unresectable stage IIIA or B NSCLC patients

          -  WHO PS 0 or 1

          -  Weight loss &lt; 5 % within the last 3 months

          -  At least one measurable lesion

          -  Planning CT scan previous to randomization

          -  Written informed consent

        Exclusion Criteria:

          -  Malignant effusion, supraclavicular node or SVCS

          -  PTV &gt; 2000 cm3

          -  V20 &gt; 35%

          -  FEV1 and DLCO both &lt; 30% or 1 liter at study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pilar Garrido, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Ramon y Cajal (Madrid)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Rosell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2012</study_first_submitted>
  <study_first_submitted_qc>July 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2012</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LUNG</keyword>
  <keyword>DOCETAXEL</keyword>
  <keyword>GEMCITABINE</keyword>
  <keyword>CARBOPLATIN</keyword>
  <keyword>RADIOTHERAPY</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

